Hyderabad | December 18, 2025: As the holiday season approaches, travel, winter weather, and busy lifestyles often lead to joint stiffness, back pain, and everyday musculoskeletal strain. CURAPOD, a Made-in-India health-tech brand backed by Litemed, offers a clinically validated, personalised wearable solution that makes an ideal gift for loved ones this festive season. The device is India’s first non-invasive, personalised pain-management solution, registered with the Central Drugs Standard Control Organization (CDSCO) and the FDA. It provides pain relief across more than 30 conditions, including chronic back pain, arthritis, tendonitis, sports injuries, and everyday strain. 100% drug-free and side-effect-free, with a 1-year warranty and free expert consultation, CURAPOD ensures fast, reliable relief for home, travel, and winter wellness routines.
The device uses medical-grade photobiomodulation technology to deliver targeted red and near-infrared light that promotes cellular repair, reduces inflammation, and accelerates recovery. Its adaptive engine personalises therapy in real time based on muscle response, often providing unnoticeable relief within 30 minutes.
“The holiday season can be tough on joints and muscles, especially during long travels or winter activities. CURAPOD’s personalised adaptive therapy allows users to maintain their routines and enjoy festive travel without being slowed down by pain,” said Surya Maguluri, Founder & Chief Technology Officer, CURAPOD, backed by Litemed India Private Limited. “Its ability to deliver targeted pain relief, adapt intensity based on user comfort, and offer consistent, non-invasive support makes it a reliable health-tech solution for everyday wellness.”
“CURAPOD is designed to make advanced, personalised pain relief accessible and convenient for everyday use, whether at home, during travel, or through winter routines,” said Sri Velliyur, Co-Founder & CEO, CURAPOD. “Our goal is to make advanced, non-invasive pain relief a seamless part of daily life, while also offering a thoughtful option for those looking to support the well-being of friends and family this holiday season.”
CURAPOD is priced at ₹8,399 and can be used according to the pain condition and intensity, following defined protocols. It is currently available across India through their D2C website and will be listed on leading marketplaces from the first quarter of 2026, with broader retail and e-commerce expansion planned over the following two years.
As families plan festive travel and set health goals for 2026, CURAPOD positions itself as the ideal lifestyle companion, combining adaptive, clinically validated therapy with user-friendly technology for measurable, personalised pain relief anytime, anywhere.
